185 related articles for article (PubMed ID: 37814415)
1. The application of podocyte antigen PLA2R and anti-PLA2R antibody in the diagnosis and treatment of membranous nephropathy.
Chen Y; Xu Y; Chen S; Yu Y; Zhu X; Chen J
Ren Fail; 2023; 45(2):2264939. PubMed ID: 37814415
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Characteristics and Outcomes of PLA
Luo J; Yuan Y; Tian J; Zhou Z; Su C; Yang F; Wang G
Am J Kidney Dis; 2022 Sep; 80(3):364-372. PubMed ID: 35288217
[TBL] [Abstract][Full Text] [Related]
3. Seropositive PLA2R-associated membranous nephropathy but biopsy-negative PLA2R staining.
Luo J; Zhang W; Su C; Zhou Z; Wang G
Nephrol Dial Transplant; 2021 Dec; 36(12):2216-2223. PubMed ID: 33236093
[TBL] [Abstract][Full Text] [Related]
4. The association of serum anti-PLA2R antibody and glomerular PLA2R antigen staining with clinical manifestations and outcomes in membranous nephropathy.
Yang SF; Xie XF; Lu WH; Lan P; Liu H; Jin L
Clin Exp Nephrol; 2023 Dec; 27(12):1060-1066. PubMed ID: 37668806
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies.
Li X; Shen Y; Li Y; Ma L; Sun Q
Ren Fail; 2024 Dec; 46(1):2297015. PubMed ID: 38275176
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study.
Yin P; Wang J; Liang W; Zhan L; Liu Y; Lin J; Chen X; He Y; Jian H; Xie Z; Tan X; Ye Q; Huang F
Ren Fail; 2020 Nov; 42(1):675-683. PubMed ID: 32674643
[TBL] [Abstract][Full Text] [Related]
7. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
Li C; Li H; Wen YB; Li XM; Li XW
BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
[TBL] [Abstract][Full Text] [Related]
8. Relationship between the status of phospholipase A2 receptor and prognosis of idiopathic membranous nephropathy.
Li YQ; Liu ZZ; Lin KX; Liu RH; Ni L; Liu GX; Lan HY; Shi YJ
Nephrology (Carlton); 2020 Feb; 25(2):144-149. PubMed ID: 31226230
[TBL] [Abstract][Full Text] [Related]
9. The Role of Renal PLA2R Staining Combined with Serum PLA2R Antibody in Membranous Nephropathy Risk Stratification.
Hu X; Wang X; Yu X; Ni L; Gao C; Pan X; Ren H; Xu J; Ma J
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202076
[TBL] [Abstract][Full Text] [Related]
10. Primary Membranous Nephropathy.
Couser WG
Clin J Am Soc Nephrol; 2017 Jun; 12(6):983-997. PubMed ID: 28550082
[TBL] [Abstract][Full Text] [Related]
11. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
[TBL] [Abstract][Full Text] [Related]
12. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA
Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329
[TBL] [Abstract][Full Text] [Related]
14. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.
Hoxha E; Thiele I; Zahner G; Panzer U; Harendza S; Stahl RA
J Am Soc Nephrol; 2014 Jun; 25(6):1357-66. PubMed ID: 24610926
[TBL] [Abstract][Full Text] [Related]
15. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
Guo Y; Wu X; Liu L; Zhang H; Yang L; Chen W
Ren Fail; 2020 Nov; 42(1):122-130. PubMed ID: 31957527
[No Abstract] [Full Text] [Related]
17. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients.
Wang B; Zhu Z; Huang F; Huang H; Tu L; Wang Y; Zheng L; Zhou J; Wei X
BMC Nephrol; 2022 Sep; 23(1):306. PubMed ID: 36068486
[TBL] [Abstract][Full Text] [Related]
18. Fibrinogen-albumin ratio predicts treatment response in phospholipase A2 receptor-associated membranous nephropathy with nephrotic syndrome.
Duan S; Chen S; Chen C; Lu F; Pan Y; Lu Y; Li Q; Liu S; Zhang B; Mao H; Xing C; Yuan Y
Ren Fail; 2024 Dec; 46(1):2359024. PubMed ID: 38832491
[TBL] [Abstract][Full Text] [Related]
19. The relationship of anti-phospholipase A2 receptor antibody and C5a complement with disease activity and short-term outcome in idiopathic membranous nephropathy.
Chi JN; Lai TS; Wu CF; Fu TY; Chou YH; Chiu YL; Lin WC; Chiang WC; Chen YM; Wu MS
J Formos Med Assoc; 2019 May; 118(5):898-906. PubMed ID: 30639075
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.
Pourcine F; Dahan K; Mihout F; Cachanado M; Brocheriou I; Debiec H; Ronco P
PLoS One; 2017; 12(3):e0173201. PubMed ID: 28257452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]